Open AccessRegarding the evidence-based use of micronized progesterone
Author(s) -
Alexander Makatsariya,
Gian Carlo Di Renzo,
Giuseppe Rizzo,
В. О. Бицадзе,
J. Kh. Khizroeva,
Е. И. Вовк,
Igor Govorov,
D. L. Guryev,
G.B. Dikke Dikke,
М. С. Зайнулина,
Н С Захарова,
В. В. Ковалев,
Eduard Komlichenko,
Vladimir Kramarskiy,
Andriy Loginov,
L. I. Maltseva,
V. B. Nemirovskiy,
D. A. Ponomarev,
Е. Б. Рудакова,
Н. В. Самбурова,
O.F. Serova,
F. K. Tetelyutina,
M. V. Tretyakova,
J. Yu Ungiadze
Publication year - 2020
Publication title -
akušerstvo, ginekologiâ i reprodukciâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.124
H-Index - 4
eISSN - 2500-3194
pISSN - 2313-7347
DOI - 10.17749/2313-7347/ob.gyn.rep.2020.171
Subject(s) - medicine , miscarriage , health professionals , covid-19 , pandemic , social media , medical education , health care , family medicine , pregnancy , pathology , genetics , political science , law , biology , disease , infectious disease (medical specialty) , economics , economic growth
An issue of habitual miscarriage poses a high social importance especially during COVID-19 pandemic. Meanwhile, healthcareworkers faced a mass media campaign against using micronized progesterone upon habitual miscarriage, which, as viewed by us, displays signs of prejudiced data manipulation and may disorient practitioners. In this Letter we provide objective information on accumulated data regarding gestagenes efficacy and safety. We invoke healthcare professionals to make decisions deserving independent primary source trust presented by original scientific papers published in peer-reviewed journals, clinical recommendations proposed by professional medical communities as well as treatment standards and protocols.